DUGAN RICHARD W 4
4 · Vanda Pharmaceuticals Inc. · Filed Jun 2, 2022
Insider Transaction Report
Form 4
DUGAN RICHARD W
Director
Transactions
- Exercise/Conversion
Common Stock
2022-05-31$4.15/sh+15,000$62,250→ 74,887 total - Sale
Common Stock
2022-05-31$9.85/sh−6,500$64,052→ 68,387 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-05-31−15,000→ 0 totalExercise: $4.15Exp: 2022-06-13→ Common Stock (15,000 underlying)
Footnotes (3)
- [F1]Represents shares of the Issuer's common stock sold to satisfy the exercise price of the stock options, which were scheduled to expire June 13, 2022 as reflected in this Form 4.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.75 to $9.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The option vested in 12 equal monthly installments beginning on July 14, 2012.